Savara (SVRA) Long-Term Debt Issuances (2016 - 2025)

Savara's (SVRA) quarterly Long-Term Debt Issuances came in at $29.6 million in Q1 2025, up 5658.37% on a QoQ basis from $514000.0 in Q1 2020.

Savara (SVRA) Long-Term Debt Issuances (2016 - 2025) Analysis & Trends

Savara (SVRA) has 3 years of Long-Term Debt Issuances data on file, last reported at $29.6 million in Q1 2025.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $29.6 million in Q1 2025; TTM through Dec 2025 was $29.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $29.6 million, changed N/A from the prior year.
Long-Term Debt Issuances for Q1 2025 stood at $29.6 million, up from $514000.0 in the prior quarter.
Over the last five years, Long-Term Debt Issuances for SVRA reached as high as $29.6 million in Q1 2025 and fell as low as $29.6 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Savara	1.24 Bn	1.24 Bn	-	-

Download Data